<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03341910</url>
  </required_header>
  <id_info>
    <org_study_id>DFD-03-CD-008</org_study_id>
    <nct_id>NCT03341910</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety and Local Tolerability of DFD-03 (Tazarotene) Lotion, 0.1% Compared to Tazorac® Cream, 0.1% in the Topical Treatment of Acne Vulgaris</brief_title>
  <official_title>A Randomized, Double-Blind, Active-Controlled Study to Assess the Safety and Local Tolerability of DFD-03 (Tazarotene) Lotion, 0.1% Compared to Tazorac® (Tazarotene) Cream, 0.1% in the Topical Treatment of Acne Vulgaris for 12 Weeks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study for Subjects with mild to moderate facial acne vulgaris. During the 12-week treatment&#xD;
      period subjects randomized to DFD-03 Lotion or Vehicle Lotion will use the study drug twice&#xD;
      daily. Subjects randomized to Tazorac Cream or Vehicle Cream will use the study drug once&#xD;
      daily in the evening. Safety assessments will include the investigator's assessment of local&#xD;
      cutaneous tolerance/application site reactions on the face, vital signs and adverse events.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A study for Subjects with mild to moderate facial acne vulgaris. Subjects will be randomized&#xD;
      to treatment with either DFD-03 (tazarotene) Lotion 0.1%, Tazorac (tazarotene) Cream, 0.1%,&#xD;
      Vehicle Lotion or Vehicle Cream. During the 12-week treatment period subjects randomized to&#xD;
      DFD-03 Lotion or Vehicle Lotion will use the study drug twice daily. Subjects randomized to&#xD;
      Tazorac Cream or Vehicle Cream will use the study drug once daily in the evening. Subjects&#xD;
      will be instructed to treat the entire face.&#xD;
&#xD;
      Safety assessments will include the investigator's assessment of local cutaneous&#xD;
      tolerance/application site reactions on the face, vital signs and adverse events. Urine&#xD;
      pregnancy tests will be performed for all female subjects. A physical examination will be&#xD;
      performed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 21, 2017</start_date>
  <completion_date type="Actual">May 18, 2018</completion_date>
  <primary_completion_date type="Actual">May 18, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Event Occurences in DFD-03 Lotion Versus Tazorac Cream Groups</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Frequency count of treatment emergent adverse events will be compared between DFD-03 Lotion and Tazorac Cream groups.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">155</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>DFD-03 Lotion, 0.1%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DFD-03 Lotion, 0.1% to be applied twice daily approximately 12 hours apart, for 1 minute and rinsed off</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tazorac Cream, 0.1%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tazorac Cream, 0.1% to be applied once in the evening and left overnight for approximately 12 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Lotion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle Lotion to be applied twice daily for 1 minute and rinsed off</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle Cream to be applied once in the evening and left overnight for approximately 12 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DFD-03 Lotion, 0.1%</intervention_name>
    <description>DFD-03 Lotion will be applied to the face (avoiding areas around the eyes and mouth) twice daily, approximately 12 hours apart, and washed off after 1 minute.</description>
    <arm_group_label>DFD-03 Lotion, 0.1%</arm_group_label>
    <other_name>Tazarotene Lotion, 0.1%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tazorac Cream, 0.1%</intervention_name>
    <description>Tazorac Cream will be applied to the face (avoiding areas around the eyes and mouth) once daily in the evening and left on overnight.</description>
    <arm_group_label>Tazorac Cream, 0.1%</arm_group_label>
    <other_name>Tazarotene Cream, 0.1%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DFD-03 Vehicle Lotion 0%</intervention_name>
    <description>Vehicle Lotion will be applied to the face (avoiding areas around the eyes and mouth) twice daily, approximately 12 hours apart, and washed off after 1 minute.</description>
    <arm_group_label>Vehicle Lotion</arm_group_label>
    <other_name>Vehicle Lotion 0%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tazorac Vehicle Cream 0%</intervention_name>
    <description>Vehicle Cream will be applied to the face (avoiding areas around the eyes and mouth) once daily in the evening and left on overnight.</description>
    <arm_group_label>Vehicle Cream</arm_group_label>
    <other_name>Vehicle Cream 0%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject must be at least 12 years of age. At selected site(s), a total of&#xD;
             approximately eight subjects 9-11 years of age will be enrolled into the 2 arms of&#xD;
             DFD-03 lotion group (active and vehicle).&#xD;
&#xD;
          2. A clinical diagnosis of facial acne vulgaris with a facial Investigator's Global&#xD;
             Assessment (IGA) score of 2 (mild) to 3 (moderate) at Baseline. At selected site(s),&#xD;
             up to twelve subjects with acne lesions on the chest and/or back (including shoulders)&#xD;
             in addition to those on the face will treat their chest and/or back (including&#xD;
             shoulders) in addition to their face.&#xD;
&#xD;
          3. Inflammatory lesion count (papules and pustules) of at least 20, non-inflammatory&#xD;
             lesion count (closed and open comedones) of at least 25 on the face including the&#xD;
             nose, and no more than 2 nodulocystic lesions. This criteria is not applicable to the&#xD;
             9-11 years age group as long as subjects have an IGA score of 2 (mild) to 3 (moderate)&#xD;
             at Baseline.&#xD;
&#xD;
          4. Females, regardless of childbearing potential: Must have a negative urine pregnancy&#xD;
             test and if sexually active, must be on or use an acceptable method of birth control.&#xD;
&#xD;
          5. Subjects agree not to use any product on the face during the entire course of study&#xD;
             except for non-medicated, investigator-approved cleanser, sunscreen, face wash, and&#xD;
             make-up as instructed by the investigator.&#xD;
&#xD;
          6. Subjects must be willing to comply with sun avoidance measures for the face, including&#xD;
             use of investigator-approved sunscreen and/or hats, have limited sun exposure time,&#xD;
             and have no tanning bed use.&#xD;
&#xD;
          7. Subject must be in good general health as determined by the investigator and supported&#xD;
             by the medical history, physical examination and vital signs.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Females who are pregnant or lactating or planning to become pregnant during the study&#xD;
             period.&#xD;
&#xD;
          2. Treatment with the following products:&#xD;
&#xD;
             Topical acne treatments or other topical facial medication in the 14 days prior to&#xD;
             Baseline Systemic corticosteroids and systemic acne treatments in the 30 days prior to&#xD;
             Baseline Systemic retinoid use in the 180 days prior to Baseline Undertaken certain&#xD;
             facial procedures such as chemical peel, laser treatment, photodynamic therapy, acne&#xD;
             surgery, cryodestruction or chemodestruction, x-ray therapy, intralesional steroids,&#xD;
             dermabrasion, or depilation (except eyebrow shaping) in 30 days prior to Baseline.&#xD;
&#xD;
             Treatment with a medication or procedure that, in the opinion of the investigator,&#xD;
             would put the subject at unacceptable risk for participation in the study or may&#xD;
             interfere with evaluations in the study.&#xD;
&#xD;
             Treatment with an investigational product or device in 30 days prior to Baseline.&#xD;
&#xD;
          3. Known allergic reaction to retinoids or tazarotene or any of the product ingredients.&#xD;
&#xD;
          4. Presence of any facial skin disease or condition that would interfere with the study&#xD;
             or place the subject at unacceptable risk including sunburn, rosacea, seborrheic&#xD;
             dermatitis, perioral dermatitis, lupus, dermatomyositis, psoriasis, eczema, squamous&#xD;
             cell carcinoma, acneiform eruptions caused by medications, steroid acne, steroid&#xD;
             folliculitis, bacterial folliculitis or any other facial disease or condition.&#xD;
&#xD;
          5. Subjects with a serious and or chronic medical condition such as chronic or active&#xD;
             liver disease, renal impairment, heart disease, severe respiratory disease, rheumatoid&#xD;
             arthritis, current malignancies, immunocompromised conditions, or any other disease&#xD;
             that, in the opinion of the investigator, would interfere with the study or place the&#xD;
             subject at unacceptable risk.&#xD;
&#xD;
          6. Subjects who have been treated for alcohol dependence or alcohol or drug abuse in the&#xD;
             year.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Srinivas R. Sidgiddi, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Dr. Reddy's Laboratories Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>International Dermatology Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>October 13, 2017</study_first_submitted>
  <study_first_submitted_qc>November 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2017</study_first_posted>
  <results_first_submitted>July 30, 2020</results_first_submitted>
  <results_first_submitted_qc>August 13, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 17, 2020</results_first_posted>
  <disposition_first_submitted>September 24, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>August 13, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">August 17, 2020</disposition_first_posted>
  <last_update_submitted>August 13, 2020</last_update_submitted>
  <last_update_submitted_qc>August 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotinic Acids</mesh_term>
    <mesh_term>Tazarotene</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 6, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT03341910/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 11, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT03341910/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>DFD-03 Lotion, 0.1%</title>
          <description>DFD-03 Lotion, 0.1% to be applied twice daily approximately 12 hours apart, for 1 minute and rinsed off&#xD;
DFD-03 Lotion, 0.1%: DFD-03 Lotion will be applied to the face (avoiding areas around the eyes and mouth) twice daily, approximately 12 hours apart, and washed off after 1 minute.</description>
        </group>
        <group group_id="P2">
          <title>Tazorac Cream, 0.1%</title>
          <description>Tazorac Cream, 0.1% to be applied once in the evening and left overnight for approximately 12 hours&#xD;
Tazorac Cream, 0.1%: Tazorac Cream will be applied to the face (avoiding areas around the eyes and mouth) once daily in the evening and left on overnight.</description>
        </group>
        <group group_id="P3">
          <title>DFD-03 Vehicle Lotion</title>
          <description>Vehicle Lotion to be applied twice daily for 1 minute and rinsed off&#xD;
DFD-03 Vehicle Lotion 0%: Vehicle Lotion will be applied to the face (avoiding areas around the eyes and mouth) twice daily, approximately 12 hours apart, and washed off after 1 minute.</description>
        </group>
        <group group_id="P4">
          <title>Tazorac Vehicle Cream</title>
          <description>Vehicle Cream to be applied once in the evening and left overnight for approximately 12 hours&#xD;
Tazorac Vehicle Cream 0%: Vehicle Cream will be applied to the face (avoiding areas around the eyes and mouth) once daily in the evening and left on overnight.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="49"/>
                <participants group_id="P3" count="26"/>
                <participants group_id="P4" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="49"/>
                <participants group_id="P3" count="26"/>
                <participants group_id="P4" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Population - All subjects who received study product and provided any post-baseline safety information.</population>
      <group_list>
        <group group_id="B1">
          <title>DFD-03 Lotion, 0.1%</title>
          <description>DFD-03 Lotion, 0.1% to be applied twice daily approximately 12 hours apart, for 1 minute and rinsed off&#xD;
DFD-03 Lotion, 0.1%: DFD-03 Lotion will be applied to the face (avoiding areas around the eyes and mouth) twice daily, approximately 12 hours apart, and washed off after 1 minute.</description>
        </group>
        <group group_id="B2">
          <title>Tazorac Cream, 0.1%</title>
          <description>Tazorac Cream, 0.1% to be applied once in the evening and left overnight for approximately 12 hours&#xD;
Tazorac Cream, 0.1%: Tazorac Cream will be applied to the face (avoiding areas around the eyes and mouth) once daily in the evening and left on overnight.</description>
        </group>
        <group group_id="B3">
          <title>DFD-03 Vehicle Lotion</title>
          <description>Vehicle Lotion to be applied twice daily for 1 minute and rinsed off&#xD;
DFD-03 Vehicle Lotion 0%: Vehicle Lotion will be applied to the face (avoiding areas around the eyes and mouth) twice daily, approximately 12 hours apart, and washed off after 1 minute.</description>
        </group>
        <group group_id="B4">
          <title>Tazorac Vehicle Cream</title>
          <description>Vehicle Cream to be applied once in the evening and left overnight for approximately 12 hours&#xD;
Tazorac Vehicle Cream 0%: Vehicle Cream will be applied to the face (avoiding areas around the eyes and mouth) once daily in the evening and left on overnight.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="54"/>
            <count group_id="B2" value="49"/>
            <count group_id="B3" value="26"/>
            <count group_id="B4" value="26"/>
            <count group_id="B5" value="155"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="103"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.9" spread="9.5"/>
                    <measurement group_id="B2" value="23.1" spread="8.9"/>
                    <measurement group_id="B3" value="22.0" spread="9.7"/>
                    <measurement group_id="B4" value="25.0" spread="10.5"/>
                    <measurement group_id="B5" value="22.8" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="76"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="128"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adverse Event Occurences in DFD-03 Lotion Versus Tazorac Cream Groups</title>
        <description>Frequency count of treatment emergent adverse events will be compared between DFD-03 Lotion and Tazorac Cream groups.</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>Safety Population - All subjects who received study product and provided any post baseline safety information.</population>
        <group_list>
          <group group_id="O1">
            <title>DFD-03 Lotion, 0.1%</title>
            <description>DFD-03 Lotion, 0.1% to be applied twice daily approximately 12 hours apart, for 1 minute and rinsed off&#xD;
DFD-03 Lotion, 0.1%: DFD-03 Lotion will be applied to the face (avoiding areas around the eyes and mouth) twice daily, approximately 12 hours apart, and washed off after 1 minute.</description>
          </group>
          <group group_id="O2">
            <title>Tazorac Cream, 0.1%</title>
            <description>Tazorac Cream, 0.1% to be applied once in the evening and left overnight for approximately 12 hours&#xD;
Tazorac Cream, 0.1%: Tazorac Cream will be applied to the face (avoiding areas around the eyes and mouth) once daily in the evening and left on overnight.</description>
          </group>
          <group group_id="O3">
            <title>DFD-03 Vehicle Lotion</title>
            <description>Vehicle Lotion to be applied twice daily for 1 minute and rinsed off&#xD;
DFD-03 Vehicle Lotion 0%: Vehicle Lotion will be applied to the face (avoiding areas around the eyes and mouth) twice daily, approximately 12 hours apart, and washed off after 1 minute.</description>
          </group>
          <group group_id="O4">
            <title>Tazorac Vehicle Cream</title>
            <description>Vehicle Cream to be applied once in the evening and left overnight for approximately 12 hours&#xD;
Tazorac Vehicle Cream 0%: Vehicle Cream will be applied to the face (avoiding areas around the eyes and mouth) once daily in the evening and left on overnight.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Event Occurences in DFD-03 Lotion Versus Tazorac Cream Groups</title>
          <description>Frequency count of treatment emergent adverse events will be compared between DFD-03 Lotion and Tazorac Cream groups.</description>
          <population>Safety Population - All subjects who received study product and provided any post baseline safety information.</population>
          <units>Adverse Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="81"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from treatment initiation until study product treatment discontinuation (approximately 12 weeks).</time_frame>
      <desc>Adverse events were collected from treatment initiation until study product treatment discontinuation (approximately 12 weeks). Spontaneously reported SAEs, which were reported up to 30 days after discontinuing study product use (approximately 4 months).</desc>
      <group_list>
        <group group_id="E1">
          <title>DFD-03 Lotion, 0.1%</title>
          <description>DFD-03 Lotion, 0.1% was applied twice daily approximately 12 hours apart, for 1 minute and rinsed off&#xD;
DFD-03 Lotion, 0.1%: DFD-03 Lotion was applied to the face (avoiding areas around the eyes and mouth) twice daily, approximately 12 hours apart, and washed off after 1 minute.</description>
        </group>
        <group group_id="E2">
          <title>Tazorac Cream, 0.1%</title>
          <description>Tazorac Cream, 0.1% was applied once in the evening and left overnight for approximately 12 hours&#xD;
Tazorac Cream, 0.1%: Tazorac Cream was applied to the face (avoiding areas around the eyes and mouth) once daily in the evening and left on overnight.</description>
        </group>
        <group group_id="E3">
          <title>Vehicle Lotion</title>
          <description>Vehicle Lotion was applied twice daily for 1 minute and rinsed off&#xD;
DFD-03 Vehicle Lotion 0%: Vehicle Lotion was applied to the face (avoiding areas around the eyes and mouth) twice daily, approximately 12 hours apart, and washed off after 1 minute.</description>
        </group>
        <group group_id="E4">
          <title>Vehicle Cream</title>
          <description>Vehicle Cream was applied once in the evening and left overnight for approximately 12 hours&#xD;
Tazorac Vehicle Cream 0%: Vehicle Cream was applied to the face (avoiding areas around the eyes and mouth) once daily in the evening and left on overnight.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site dryness</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="54"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="49"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Application site exfoliation</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="54"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="49"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Application Site Pain</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="54"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="49"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Application Site Erythema</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="54"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="49"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Application Site Pruritus</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="54"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Srinivas Sidgiddi, Sr. Director, Clinical Development</name_or_title>
      <organization>Dr. Reddy's Laboratories, Inc</organization>
      <phone>609-375-9910</phone>
      <email>srinivassidgiddi@drreddys.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

